Literature DB >> 1505614

Steady state pharmacokinetic profile of indomethacin in elderly patients and young volunteers.

J C McElnay1, A P Passmore, V L Crawford, J G McConnell, I C Taylor, F S Walker.   

Abstract

The steady-state pharmacokinetic profile of indomethacin was examined in twelve healthy volunteers (4 m, 8 f; 20-34 y) and in 12 elderly subjects (7 m, 5 f; 70-88 y). Two formulations of indomethacin were examined, providing duplicate data for each subject group. The subjects received each formulation of indomethacin (25 mg tid) for 6 days in a single blind crossover fashion. On day 7, after an overnight fast, a final 25 mg dose of indomethacin was given and plasma concentrations measured over the following 12 h. Kinetic parameters Cpmin, Tmax and AUC (0-12 h) were determined. There were no differences in the pharmacokinetic parameters between young and elderly subjects or between data for the two formulations of indomethacin. AUC values (micrograms.ml-1.h), for example, for the two formulations in the young subjects were 5.85 and 6.85 while the values for the elderly subjects were 6.55 and 6.50 respectively. When each treatment period was considered independently there was a significant difference between young and elderly subjects with regard to compliance. The rates of non compliance (over and under compliance) using a capsule count technique were, however, low with a mean maximum value of 5.8% being recorded for the elderly subjects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1505614     DOI: 10.1007/bf02280758

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  A high-speed liquid chromatographic analysis of indomethacin in plasma.

Authors:  G G Skellern; E G Salole
Journal:  J Chromatogr       Date:  1975-11-26

2.  CSM Update: Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions-1.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

3.  Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man.

Authors:  K C Kwan; G O Breault; E R Umbenhauer; F G McMahon; D E Duggan
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

4.  Repeat prescribing of non-steroidal anti-inflammatory drugs excluding aspirin: how careful are we?

Authors:  K Steele; K A Mills; A E Gilliland; W G Irwin; A Taggart
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-17

Review 5.  Pharmacokinetic changes in the elderly.

Authors:  W A Ritschel
Journal:  Methods Find Exp Clin Pharmacol       Date:  1987-03

6.  [Pharmacokinetics of indomethacin in the aged].

Authors:  A Traeger; M Kunze; G Stein; H Ankermann
Journal:  Z Alternsforsch       Date:  1973

Review 7.  Drug-drug and drug-disease interactions with nonsteroidal anti-inflammatory drugs.

Authors:  D C Brater
Journal:  Am J Med       Date:  1986-01-17       Impact factor: 4.965

8.  Pharmacokinetics of indomethacin.

Authors:  G Alván; M Orme; L Bertilsson; R Ekstrand; L Palmér
Journal:  Clin Pharmacol Ther       Date:  1975-09       Impact factor: 6.875

9.  The chronopharmacokinetics of indomethacin suppositories in healthy volunteers.

Authors:  A J Taggart; J C McElnay; B Kerr; P Passmore
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Influence of range of renal function and liver disease on predictability of creatinine clearance.

Authors:  J H Hull; L J Hak; G G Koch; W A Wargin; S L Chi; A M Mattocks
Journal:  Clin Pharmacol Ther       Date:  1981-04       Impact factor: 6.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.